Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Infinity Pharmaceuticals Inc INFIQ

Healthcare Biotechnology
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K... see more

Recent & Breaking News (GREY:INFIQ)

Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Earnings Miss Estimates

Benzinga.com  April 18, 2017

15 Biggest Mid-Day Gainers For Monday

Benzinga.com  April 3, 2017

Updated Phase 1 Data for IPI-549 Presented at AACR Annual Meeting 2017

PR Newswire April 1, 2017

Research Reports Coverage on Biotech Stocks -- Inotek Pharma, Infinity Pharma, Navidea Biopharma, and Cellectar Biosciences

PR Newswire March 16, 2017

Infinity Provides Company Update and Reports Fourth Quarter 2016 Financial Results

PR Newswire March 14, 2017

IPI-549 Featured at 15th International Congress on Targeted Anticancer Therapies

PR Newswire March 6, 2017

Infinity Announces Presentation on IPI-549 at AACR Annual Meeting

PR Newswire March 2, 2017

Infinity Announces the Date of Its Full-Year 2016 Financial Results Conference Call and Webcast

PR Newswire February 28, 2017

Infinity to Present at 37th Annual Cowen and Company Healthcare Conference

PR Newswire February 27, 2017

Infinity Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer

PR Newswire February 13, 2017

Infinity to Present at the 2017 BIO CEO & Investor Conference

PR Newswire February 6, 2017

Research Reports Initiation on Biotech Stocks -- Jazz Pharma, Infinity Pharma, Acorda Therapeutics, and Ultragenyx Pharma

PR Newswire January 30, 2017

15 Biggest Mid-Day Gainers For Monday

Benzinga.com  January 23, 2017

20 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  January 23, 2017

Infinity Presents Preclinical Data and Phase 1 Clinical Data on IPI-549 at PI3K Keystone Symposia Conference

PR Newswire January 20, 2017

Infinity Provides 2017 Goals and Financial Guidance

PR Newswire January 9, 2017

Infinity To Present At 35th Annual J.P. Morgan Annual Healthcare Conference

PR Newswire January 5, 2017

Infinity Announces Organizational Changes

PR Newswire January 4, 2017

Infinity Provides Company Update and Reports Third Quarter 2016 Financial Results

PR Newswire November 9, 2016

Infinity Announces Second Publication on PI3K-Gamma in Nature

PR Newswire November 9, 2016